TrialThe British journal of ophthalmology2023

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.

Neil M Bressler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.